A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA
The goal of this study is to genrate evidence on long-term effectiveness and safety of SKYTROFA (lonapegsomatropin) in patients with growth hormone deficiency under routine clinical care
| Condition(s) | Growth Hormone Deficiency |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | The goal of this study is to genrate evidence on long-term effectiveness and safety of SKYTROFA (lonapegsomatropin) in patients with growth hormone deficiency under routine clinical care |
| Who can participate | Inclusion Criteria: * Patients who are on treatment with SKYTROFA (lonapegsomatropin) * Patients being clinically managed in USA * Patients with an appropriate written informed consent/assent as applicable for the age of the patient Exclusion Criteria: * Patients participating in any interventional clinical study |
| Sex | All |
| Lead sponsor | Ascendis Pharma Endocrinology Division A/S |
| Locations | Phoenix, Arizona, United States; Orange, California, United States; Sacramento, California, United States; San Francisco, California, United States; Centennial, Colorado, United States; Washington D.C., District of Columbia, United States (+21 more sites) |
| Start date | 2023-03-20 |
| NCT ID | NCT05820672 |
| Official listing | https://clinicaltrials.gov/study/NCT05820672 |